Top

Published in:

19-07-2023 | Migraine | Original Communication

Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study

Authors: Fabrizio Vernieri, Nicoletta Brunelli, Simona Guerzoni, Luigi Francesco Iannone, Carlo Baraldi, Renata Rao, Francesca Schiano di Cola, Raffaele Ornello, Sabina Cevoli, Carlo Lovati, Maria Albanese, Armando Perrotta, Ilaria Cetta, Sergio Soeren Rossi, Valentina Taranta, Massimo Filippi, Pierangelo Geppetti, Simona Sacco, Claudia Altamura

Published in: Journal of Neurology | Issue 11/2023

Abstract

Background

The outcome of migraine patients retreated with monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (anti-CGRP) or its receptor (anti-CGRPr) is not completely known.

Methods

This multicentric prospective observational cohort study assessed monthly migraine days (MMDs), migraine acute medication intake (MAMI), and HIT-6 at baseline, after 90–112 days (Rev-1), after 84–90 days since Rev-1 (Rev-2) and 30 days after the last injection of anti-CGRP/CGRPr mAbs (Year-end), in the first and the second year after a discontinuation period.

Results

We enrolled 226 patients (79.6% with chronic migraine; 55.3% on erenumab and 44.7% on galcanezumab or fremanezumab). MMDs, MAMI, and HIT-6—did not differ at the respective first and second-year evaluations in the entire cohort, and comparing anti-CGRP with anti-CGRPr Abs. MMDs (18.1 ± 7.8 vs. 3.4 ± 7.8), MAMI (26.7 ± 28.3 vs.17.7 ± 17.2), and HIT-6 scores (63.1 ± 5.9 vs. 67.1 ± 10.3) were lower in the second year than in the pre-treatment baseline (consistently, p < 0.0001). Second-year baseline MMDs were lower in patients on anti-CGRP mAbs (p = 0.001) and with lower pre-treatment baseline MMDs (p ≤ 0.001).

Conclusion

Anti-CGRP/CGRPr mAbs are effective in the second as in the first year. The use of anti-CGRP or CGRPr mAbs influenced the second-year baseline MMDs, but their effectiveness did not differ during the two treatment years.

Sacco S, Amin FM, Ashina M et al (2022) European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention—2022 update. J Headache Pain 23:67. https://doi.org/10.1186/s10194-022-01431-xCrossRefPubMedPubMedCentral

Ashina M, Goadsby PJ, Reuter U et al (2019) Long-term safety and tolerability of erenumab: three-plus year results from a 5-year open-label extension study in episodic migraine. Cephalalgia 39:1455–1464. https://doi.org/10.1177/0333102419854082CrossRefPubMedPubMedCentral

Pozo-Rosich P, Detke HC, Wang S et al (2022) Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study. Curr Med Res Opin. https://doi.org/10.1080/03007995.2022.2059975CrossRefPubMed

Ashina M, Goadsby PJ, Reuter U et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28:1716–1725. https://doi.org/10.1111/ENE.14715CrossRefPubMedPubMedCentral

Drellia K, Kokoti L, Deligianni CI et al (2021) Anti-CGRP monoclonal antibodies for migraine prevention: a systematic review and likelihood to help or harm analysis. Cephalalgia 41:851–864. https://doi.org/10.1177/0333102421989601CrossRefPubMed

Vandervorst F, Van Deun L, Van Dycke A et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain. https://doi.org/10.1186/s10194-021-01335-2CrossRefPubMedPubMedCentral

Reuter U, Ehrlich M, Gendolla A et al (2022) Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42:108–118. https://doi.org/10.1177/03331024211053571CrossRefPubMed

Hepp Z, Dodick DW, Varon SF et al (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35:478–488. https://doi.org/10.1177/0333102414547138CrossRefPubMed

Förderreuther S, Zhang Q, Stauffer VL et al (2018) Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies. J Headache Pain. https://doi.org/10.1186/s10194-018-0951-2CrossRefPubMedPubMedCentral

10.

Vernieri F, Altamura C, Brunelli N et al (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22:35. https://doi.org/10.1186/s10194-021-01247-1CrossRefPubMedPubMedCentral

11.

Barbanti P, Aurilia C, Cevoli S et al (2021) Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: results of the EARLY 2 study. Headache 61:1351–1363. https://doi.org/10.1111/head.14194CrossRefPubMed

12.

Vernieri F, Brunelli N, Marcosano M et al (2023) Maintenance of response and predictive factors of 1-year GalcanezumAb treatment in real-life migraine patients in Italy: the multicenter prospective cohort GARLIT study. Eur J Neurol 30:224–234. https://doi.org/10.1111/ENE.15563CrossRefPubMed

13.

Serrano D, Lipton RB, Scher AI et al (2017) Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design. J Headache Pain 18:101. https://doi.org/10.1186/s10194-017-0787-1CrossRefPubMedPubMedCentral

14.

Gantenbein AR, Agosti R, Gobbi C et al (2021) Impact on monthly migraine days of discontinuing anti-CGRP antibodies after one year of treatment—a real-life cohort study. Cephalalgia. https://doi.org/10.1177/03331024211014616CrossRefPubMedPubMedCentral

15.

De Matteis E, Affaitati G, Frattale I et al (2021) Early outcomes of migraine after erenumab discontinuation: data from a real-life setting. Neurol Sci 42:3297–3303. https://doi.org/10.1007/s10072-020-05022-zCrossRefPubMed

16.

Raffaelli B, Terhart M, Overeem LH et al (2021) Migraine evolution after the cessation of CGRP(-receptor) antibody prophylaxis: a prospective, longitudinal cohort study. Cephalalgia. https://doi.org/10.1177/03331024211046617CrossRefPubMedPubMedCentral

17.

Vernieri F, Brunelli N, Messina R et al (2021) Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study. J Headache Pain 22:154. https://doi.org/10.1186/s10194-021-01363-yCrossRefPubMedPubMedCentral

18.

Iannone LF, Fattori D, Benemei S et al (2022) Predictors of sustained response and effects of the discontinuation of anti-calcitonin gene related peptide antibodies and reinitiation in resistant chronic migraine. Eur J Neurol 29:1505–1513. https://doi.org/10.1111/ENE.15260CrossRefPubMed

19.

Raffaelli B, Terhart M, Mecklenburg J et al (2022) Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience. J Headache Pain. https://doi.org/10.1186/S10194-022-01417-9CrossRefPubMedPubMedCentral

20.

Headache Classification Committee of the International Headache Society (IHS) (2018) The International classification of headache disorders, 3rd edition. Cephalalgia 38:1–211. https://doi.org/10.1177/0333102417738202CrossRef

21.

Sacco S, Bendtsen L, Ashina M et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20:6. https://doi.org/10.1186/s10194-018-0955-yCrossRefPubMedPubMedCentral

22.

Ornello R, Baraldi C, Guerzoni S et al (2022) Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. J Headache Pain 23:38. https://doi.org/10.1186/S10194-022-01408-WCrossRefPubMedPubMedCentral

23.

Do TP, Hougaard A, Dussor G et al (2023) Migraine attacks are of peripheral origin: the debate goes on. J Headache Pain 24:3. https://doi.org/10.1186/s10194-022-01538-1CrossRefPubMedPubMedCentral

24.

Edvinsson L, Haanes KA, Warfvinge K, DiN K (2018) CGRP as the target of new migraine therapies—successful translation from bench to clinic. Nat Rev Neurol 14:338–350. https://doi.org/10.1038/s41582-018-0003-1CrossRefPubMed

25.

Pellesi L, Do TP, Ashina H et al (2020) Review articles dual therapy with anti-CGRP monoclonal antibodies and botulinum toxin for migraine prevention: Is there a rationale? Headache. Headache 60:1056–1065. https://doi.org/10.1111/head.13843CrossRefPubMed

26.

Blumenfeld AM, Frishberg BM, Schim JD et al (2021) Real-world evidence for control of chronic migraine patients receiving CGRP monoclonal antibody therapy added to OnabotulinumtoxinA: a retrospective chart review. Pain Ther 10:809–826. https://doi.org/10.1007/s40122-021-00264-xCrossRefPubMedPubMedCentral

27.

De Logu F, Nassini R, Hegron A et al (2022) Schwann cell endosome CGRP signals elicit periorbital mechanical allodynia in mice. Nat Commun. https://doi.org/10.1038/S41467-022-28204-ZCrossRefPubMedPubMedCentral

28.

Mullin K, Kudrow D, Croop R et al (2020) Potential for treatment benefit of small molecule CGRP receptor antagonist plus monoclonal antibody in migraine therapy. Neurology 94:e2121–e2125. https://doi.org/10.1212/WNL.0000000000008944CrossRefPubMedPubMedCentral

29.

Barbanti P, Egeo G, Mitsikostas DD (2019) Trigeminal-targeted treatments in migraine: Is 60% the magic number? Headache 59:1659–1661. https://doi.org/10.1111/head.13635CrossRefPubMed

30.

Sebastianelli G, Casillo F, Di Renzo A et al (2023) Effects of botulinum toxin Type A on the nociceptive and lemniscal somatosensory systems in chronic migraine: an electrophysiological study. Toxins (Basel) 15:76. https://doi.org/10.3390/TOXINS15010076CrossRefPubMed

31.

Casillo F, Sebastianelli G, Di Renzo A et al (2022) The monoclonal CGRP-receptor blocking antibody erenumab has different effects on brainstem and cortical sensory-evoked responses. Cephalalgia 42:1236–1245. https://doi.org/10.1177/03331024221103811CrossRefPubMed

32.

Grazzi L, Andrasik F, Rizzoli P et al (2021) Acceptance and commitment therapy for high frequency episodic migraine without aura: Findings from a randomized pilot investigation. Headache 61:895–905. https://doi.org/10.1111/HEAD.14139CrossRefPubMed

33.

Fiedler-Kelly JB, Cohen-Barak O, Morris DN et al (2019) Population pharmacokinetic modelling and simulation of fremanezumab in healthy subjects and patients with migraine. Br J Clin Pharmacol 85:2721–2733. https://doi.org/10.1111/BCP.14096CrossRefPubMedPubMedCentral

34.

Kielbasa W, Quinlan T (2020) Population pharmacokinetics of galcanezumab, an anti-CGRP antibody, following subcutaneous dosing to healthy individuals and patients with migraine. J Clin Pharmacol 60:229–239. https://doi.org/10.1002/jcph.1511CrossRefPubMed

35.

de Hoon J, Van Hecken A, Vandermeulen C et al (2018) Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine. Clin Pharmacol Ther 103:815–825. https://doi.org/10.1002/CPT.799CrossRefPubMed

Title: Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study
Authors: Fabrizio Vernieri
Nicoletta Brunelli
Simona Guerzoni
Luigi Francesco Iannone
Carlo Baraldi
Renata Rao
Francesca Schiano di Cola
Raffaele Ornello
Sabina Cevoli
Carlo Lovati
Maria Albanese
Armando Perrotta
Ilaria Cetta
Sergio Soeren Rossi
Valentina Taranta
Massimo Filippi
Pierangelo Geppetti
Simona Sacco
Claudia Altamura
Publication date: 19-07-2023
Publisher: Springer Berlin Heidelberg
Keywords: Migraine
Erenumab
Galcanezumab
Fremanezumab
Published in: Journal of Neurology / Issue 11/2023
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-11872-2

2024 ASCO Annual Meeting

Springer Medicine

Retreating migraine patients in the second year with monoclonal antibodies anti-CGRP pathway: the multicenter prospective cohort RE-DO study

Abstract

Background

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2023

Efficacy of cerebellar transcranial magnetic stimulation in spinocerebellar ataxia type 3: a randomized, single-blinded, controlled trial

Anxiety and physical impairment in patients with central vestibular disorders

Evaluation of myotonometry for myotonia, muscle stiffness and elasticity in neuromuscular disorders

Peripheral nervous system involvement accompanies central nervous system involvement in anti-glial fibrillary acidic protein (GFAP) antibody-related disease

Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson’s disease

Acute necrotizing encephalopathy associated with COVID-19: case series and systematic review